Related Experiment Video
Updated: Jun 18, 2026
The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
Published on: November 19, 2008
Cell therapy for neonatal hypoxic-ischemic encephalopathy
Pedro M Pimentel-Coelho1, Rosalia Mendez-Otero
1Instituto de Ciências Biomédicas, Instituto de Biofísica Carlos Chagas Filho and Programa de Terapia Celular, UFRJ, Rio de Janeiro, Brazil. pedrompc@biof.ufrj.br
Insights
Stem cell therapies show promise for treating neonatal hypoxic-ischemic encephalopathy (HIE), a condition causing neurological disability. Research in animal models suggests potential for neuroprotection and regeneration, but clinical translation requires further investigation.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Neonatal Neurology
Background:
- Neonatal hypoxic-ischemic encephalopathy (HIE) is a significant cause of childhood neurological deficits.
- Current supportive care for HIE has limitations, with no specific treatments available.
- Stem/progenitor cell therapies are being explored for neuroprotection and regeneration in various neurological conditions.
Purpose of the Study:
- To critically review existing studies on stem/progenitor cell transplantation in animal models of HIE.
- To discuss the therapeutic potential of different stem cell types, including their mechanisms of action.
- To explore the endogenous regenerative capacity of neural stem/progenitor cells (NSCs) in the context of HIE and consider cell therapies for prematurity-related encephalopathy.
Main Methods:
- Review of preclinical studies and clinical trials involving stem/progenitor cell therapies for HIE.
- Analysis of data from animal models investigating the efficacy and mechanisms of various stem cell types (e.g., umbilical cord blood cells, mesenchymal stem cells, NSCs).
- Evaluation of NSC migration, differentiation, and neuroprotective effects in HIE models.
Main Results:
- Human umbilical cord blood mononuclear cells and mesenchymal stem/progenitor cells demonstrate therapeutic potential in HIE models via local and peripheral mechanisms.
- Neural stem/progenitor cells (NSCs) transplanted in HIE models exhibit long-distance migration to ischemic areas and differentiate into neurons.
- Studies highlight the need for further research to address critical questions before clinical application.
Conclusions:
- Stem cell transplantation holds promise for neuroprotection and regeneration in neonatal HIE.
- Understanding the endogenous regenerative potential of the neonatal brain and optimizing cell therapy strategies are crucial for clinical translation.
- Further investigation is required to establish the safety and efficacy of cell therapies for HIE and encephalopathy of prematurity.
Abstract:
Neonatal hypoxic-ischemic encephalopathy (HIE) is a common cause of long-term neurological disability in children. Despite advances in supportive care, no treatments for HIE are available at present. The potential use of stem/progenitor cell therapies for neuroprotection or regeneration of the damaged adult brain has been evaluated in several preclinical studies, and the most promising results are now being tested in clinical trials. In recent years, the use of stem/progenitor cell transplantation in animal models of HIE has also been evaluated in several laboratories. It was shown that human umbilical cord blood mononuclear cells and mesenchymal stem/progenitor cells may have a therapeutic potential through multiple mechanisms acting locally in the central nervous system and possibly in peripheral organs of hypoxic-ischemic animals. Neural stem/progenitor cells (NSCs) have also been transplanted in animal models of HIE, migrating long distances to ischemic brain areas and differentiating into neurons. The results of these studies have raised important questions that must be addressed before these findings can be translated to the bedside. In this review, we give a critical overview of the different studies published up to now, and we discuss the endogenous regenerative potential of NSCs of the newborn brain when challenged by an HIE insult. We also discuss the use of cell therapies for the encephalopathy of prematurity.
